设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

2022 年第 5 期 第 17 卷

微小RNA-1303和神经调节蛋白1在甲状腺癌组织中的表达及其临床意义

Expressions and clinical significance of microRNA-1303 and neuregulin 1 in thyroid cancer

作者:明旭1张婷婷2

英文作者:Ming Xu1 Zhang Tingting2

单位:1上海市第一人民医院上海交通大学附属第一人民医院乳腺甲状腺外科,上海201620;2复旦大学附属肿瘤医院头颈外科,上海200032

英文单位:1Department of Breast and Thyroid Surgery Shanghai General Hospital the First People′s Hospital Affiliated to Shanghai Jiao Tong University Shanghai 201620 China; 2Department of Head and Neak Surgery Fudan University Shanghai Cancer Center Shanghai 200032 China

关键词:甲状腺癌;微小RNA-1303;神经调节蛋白1

英文关键词:Thyroidcancer;MicroRNA-1303;Neuregulin1

  • 摘要:
  • 目的 探讨微小RNA-1303miR-1303)、神经调节蛋白1NRG1)在甲状腺癌组织中的表达及其临床意义。方法 选取20185月至20208月上海市第一人民医院163例行手术治疗的甲状腺疾病患者的冰冻组织标本,其中甲状腺癌99例、甲状腺腺瘤29例、桥本甲状腺炎20例、结节性甲状腺肿15例,另从本院病理科选取同期25例正常甲状腺组织标本。采用逆转录聚合酶链反应检测miR-1303在组织中的表达。采用免疫组织化学法检测NRG1的表达。分析miR-1303NRG1表达与甲状腺癌临床病理特征的关系及二者的相关性。结果 甲状腺癌、甲状腺腺瘤、桥本甲状腺炎、结节性甲状腺肿及正常甲状腺组织中miR-1303表达量分别为(1.43±0.25)(1.27±0.21)(1.19±0.11)(1.13±0.12)(1.00±0.08) 。甲状腺癌组织中miR-1303表达量高于其他甲状腺组织,差异有统计学意义(F=8.771P0.001)。甲状腺癌组织中miR-1303表达量与肿瘤大小、分化程度、包膜浸润、转移淋巴结、病理类型和TNM分期相关(均P0.001)。甲状腺癌、甲状腺腺瘤、桥本甲状腺炎、结节性甲状腺肿及正常甲状腺组织NRG1阳性表达率分别为51.5%51/99)、75.9%22/29)、80.0%16/20)、80.0%12/15)、88.0%22/25)。甲状腺癌组织NRG1阳性表达率低于其他甲状腺组织,差异有统计学意义(χ2=21.629P=0.001)。甲状腺癌组织中NRG1表达与肿瘤大小、分化程度、包膜浸润、淋巴结转移、TNM分期相关(均 P0.05)。甲状腺癌组织中miR-1303表达量与NRG1表达评分呈显著负相关(r=-0.739P=0.002)结论  miR-1303NRG1在甲状腺癌组织中的表达与肿瘤大小、分化程度、包膜浸润、淋巴结转移及TNM分期有关。甲状腺癌组织中miR-1303NRG1表达呈显著负相关。

  • Objective  To investigate the expressions of microRNA-1303 (miR-1303) and neuregulin 1 (NRG1) in thyroid cancer and those clinical significance. Methods From May 2018 to August 2020, frosty thyroid tissues from 163 patients with thyroid disease who underwent surgical therapy in Shanghai General Hospital were enrolled, including 99 cases of thyroid cancer, 29 cases of thyroid adenoma, 20 cases of Hashimotos thyroiditis, 15 cases of nodular goiter. Another 25 cases of normal thyroid in department of pathology in the hospital were selected. Reverse transcription polymerase chain reaction was used to detect the expression of miR-1303 in tissues. The expression of NRG1 was detected by immunohistochemistry. The relationship between expressions of miR-1303 and NRG1 and the relationship between both indexes and the clinicopathological features of thyroid cancer were analyzed. Results  The expression of miR-1303 in tissues of thyroid cancer, thyroid adenoma, Hashimotos thyroiditis, nodular goiter and normal thyroid was (1.43±0.25), (1.27±0.21), (1.19±0.11), (1.13±0.12) and (1.00±0.08), respectively. That in thyroid cancer tissue was higher than that in other thyroid tissues (F=8.771, P<0.001). In thyroid cancer tissue, the expression of miR-1303 was correlated with tumor site, differentiation degree, capsular infiltration, metastatic lymph nodes, pathological types and TNM stages (all P<0.001). NRG1 positive rate in tissues of thyroid cancer, thyroid adenoma, Hashimotos thyroiditis, nodular goiter and normal thyroid was 51.5%51/99, 75.9%22/29, 80.0%16/20, 80.0%12/15 and 88.0%22/25, respectively. The rate of NRG1 positive expression in thyroid cancer tissue was lower than that in other thyroid tissues(χ2=21.629, P=0.001. In thyroid cancer tissue, the expression of NRG1 was correlated with tumor site, differentiation degree, capsular infiltration, metastatic lymph node and TNM stages (all P<0.05). In thyroid cancer tissue, the expression of miR-1303 was negatively related with NRG1 expression score (r=-0.739, P=0.002). Conclusion The expression of miR-1303 and NRG1 in thyroid cancer tissue are correlated with tumor size, differentiation degree, capsular infiltration, metastatic lymph node and TNM stages. The expression of miR-1303 was negatively related with NRG1.

copyright
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址: 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭
Baidu
map